# Clinical Implementation Resources for Pharmacogenomics (CIRP)

> **NIH NIH U24** · STANFORD UNIVERSITY · 2024 · $1,469,999

## Abstract

7. Project Summary/Abstract
The success of precision medicine continues to rest on our ability to measure the genome, the environment, and the
physiological state of patients; then choose interventions that maximize efficacy and minimize adverse effects. A key
component of precision medicine is to understand pharmacogenomics (PGx) — the genetic influences on interindividual
drug response variability. Two million adverse drug reactions occur annually in the United States, which results in
roughly 100,000 deaths and costs upwards of $30 billion dollars each year. Approximately 15%-20% of FDA-approved
medications are impacted by common germline genetic variation, and their effectiveness and safety can be improved by
using genetic tests to guide prescribing. Many of these hospitalizations and deaths are preventable, prompting many health
care organizations, community, and academic medical centers to invest in genomic medicine implementation by
supporting PGx decision support and returning PGx results. For over 10 years, CPIC has provided critical resources to
translate patient genotypes into evidence-based prescribing recommendations for specific drugs. Based on these important
clinical guidelines, the Pharmacogenomics Clinical Annotation Tool (PharmCAT) provides the scientific and clinical
communities the ability to annotate raw genetic test data (genotypes, DNA sequence) with standardized PGx calls,
knowledge from the clinical guidelines and report the subsequent haplotypes, diplotypes and phenotypes with appropriate
clinical guidance via a user-friendly software pipeline. CPIC coupled with the PharmCAT software enable the global
clinical implementation of PGx in precision medicine programs. In this proposal, we outline our plan to develop the
Clinical Implementation Resources for Pharmacogenomics (CIRP) to accelerate clinical implementation of PGx research
discoveries. We will accomplish this plan by continuing the development of CPIC clinical guidelines and supporting
evidence which are then applied to genetic test results by PharmCAT for result translation and the subsequent clinical
implementation of PGx. The track record of CPIC (2009) and PharmCAT (2017) in collaboration with the PharmGKB
(2000) in serving the broad scientific and clinical community is exceptional. In this proposal, we request support to
advance the CIRP in support of genome-informed medicine and outline a plan to (1) develop and utilize innovative
approaches to create, expand, and update CPIC guidelines (2) integrate CPIC, FDA, and other publicly available
guidelines through PharmCAT and (3) disseminate PGx clinical implementation content and tools to the greater scientific
community for local and cloud-based usage.

## Key facts

- **NIH application ID:** 10925243
- **Project number:** 5U24HG013077-02
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Kelly E. Caudle
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,469,999
- **Award type:** 5
- **Project period:** 2023-09-08 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10925243

## Citation

> US National Institutes of Health, RePORTER application 10925243, Clinical Implementation Resources for Pharmacogenomics (CIRP) (5U24HG013077-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10925243. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*